Lucentis

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

FunctionNeovascular Age-Related Macular Degeneration

55 competitors in Function

#DrugCompanyPhaseTrials

1

Indocin

CCosette Pharmaceuticals, Inc.

Approved

32

Flomax

Sanofi

Phase 3

13

Taxol

Teva

Phase 2

14

N-Acetyl Cyteien

SStanford University

Phase 3

25

Ezallor Sprinkle

AstraZeneca

Phase 2

16

Xeljanz

PPrism Pharmaceuticals

Phase 2

17

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

18

Paraplatin

AAvyxa

Phase 2

19

Tuoyi

CCoherus Oncology, Inc.

Phase 2

110

Golytely

Bayer

Phase 1

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diabetic Macular Edema8 trials

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Recruiting·IIncepta Pharmaceuticals Ltd·Phase 3·NCT06305416·70 enrolled

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Terminated·NNorth Toronto Eye Care Laser and Eye Specialists·Phase 4·NCT02684084·5 enrolled

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Completed·VVitreo-Retinal Associates, Michigan·N/A·NCT01473251·16 enrolled

Show 5 more trials

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

Completed·UUniversity of Luebeck·N/A·NCT01638858·25 enrolled

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Completed·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT05217680·510 enrolled

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Completed·VVitreo-Retinal Associates, Michigan·Phase 4·NCT03097068·10 enrolled

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Completed·Novartis·Phase 2·NCT03927690·91 enrolled

Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery

Unknown status·SSecond Military Medical University·Phase 3·NCT04063358·90 enrolled

Macular Degeneration6 trials

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Completed·Chong Kun Dang Pharmaceutical·Phase 3·NCT04857177·312 enrolled

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Completed·TThe National Retina Institute·Phase 1/2·NCT00395707·20 enrolled

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Completed·BBio-Thera Solutions·Phase 3·NCT05439629·488 enrolled

Show 3 more trials

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Completed·OOphthotech Corporation·Phase 2·NCT03362190·64 enrolled

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Completed·PPfenex, Inc·Phase 1/2·NCT02121353·25 enrolled

Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration

Unknown status·OOraya Therapeutics, Inc.·N/A·NCT01521819·12 enrolled

Age-Related Macular Degeneration6 trials

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Completed·OOphthotech Corporation·Phase 2·NCT01089517·449 enrolled

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

Completed·RRetinal Consultants of Arizona·Phase 4·NCT01863199·60 enrolled

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Completed·SSamsung Bioepis Co., Ltd.·Phase 3·NCT03150589·705 enrolled

Show 3 more trials

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

Withdrawn·VVitreous -Retina- Macula Consultants of New York·Phase 2·NCT00457678

Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

Completed·SSeoul National University Hospital·Phase 4·NCT02944227·20 enrolled

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Completed·RRetinal Consultants of Arizona·Phase 1·NCT02591914·30 enrolled

Neovascular AMD4 trials

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Completed·PPanOptica, Inc.·Phase 1·NCT02022540·50 enrolled

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Completed·LLupin Ltd.·Phase 3·NCT04690556·600 enrolled

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Completed·UUniversity of Miami·Phase 2·NCT00344227·40 enrolled

Show 1 more trial

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated·UUnknown Sponsor·Phase 2·NCT05571267·1 enrolled

Wet AMD3 trials

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Completed·OOpthea Limited·Phase 1·NCT02543229·51 enrolled

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Completed·Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT03312283·48 enrolled

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Completed·SShanghai Biomabs Pharmaceutical Co., Ltd.·Phase 1·NCT04884399·24 enrolled

13 more indications

Proliferative Diabetic Retinopathy3 trials

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Unknown status·RRetina Associates, Kansas City·Phase 3·NCT00516464·40 enrolled

Retrospective Review of Proliferative Diabetic Retinopathy Patients

Unknown status·EElman Retina Group··NCT03609996·100 enrolled

Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

Completed·WWonkwang University Hospital·Phase 4·NCT02834663·25 enrolled

Efficacy and Safety2 trials

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Unknown status·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 2/3·NCT05297292·433 enrolled

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed·Shanghai Henlius Biotech·Phase 3·NCT05003245·407 enrolled

Itching1 trial

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Completed·RRetina Institute of Hawaii··NCT00804934·100 enrolled

Immunogenicity1 trial

Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®

Unknown status·AAO GENERIUM·Phase 3·NCT04667039·408 enrolled

ESS1 trial

Assessment of Color Vision in Diabetic Patients

Completed·IInstituto de Olhos de Goiania··NCT03345667·30 enrolled

Wet Age-Related Macular Degeneration1 trial

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Completed·SSanten Inc.·Phase 2·NCT03211234·76 enrolled

Function1 trial

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

Completed·UUniversity of Luebeck·N/A·NCT01269151·20 enrolled

Choroidal Neovascularization1 trial

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Completed·WWashington University School of Medicine·Phase 1·NCT00500344·17 enrolled

Treatment1 trial

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Completed·Novartis··NCT04847895·5,500 enrolled

Combination Therapy1 trial

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Unknown status·BBarnes Retina Institute·N/A·NCT00455871·30 enrolled

Retinal Vein Occlusion1 trial

Ranibizumab in Patients With Branch Retinal Vein Occlusion

Completed·MMedical University of Vienna·Phase 4·NCT01027481·30 enrolled

Neovascular Age-related Macular Degeneration1 trial

A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

Recruiting·Roche·Approved·NCT04853251·188 enrolled

Unspecified2 trials

French Evaluation Group Avastin Versus Lucentis

Completed·HHospices Civils de Lyon·Phase 3·NCT01170767·501 enrolled

Study Evaluating Genotypes Using Lucentis

Terminated·UUniversity of Utah··NCT00474695·65 enrolled

Details

Drug Info

Related News